Last reviewed · How we verify

Letermovir IV — Competitive Intelligence Brief

Letermovir IV (Letermovir IV) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CMV terminase inhibitor. Area: Infectious Disease / Virology.

phase 3 CMV terminase inhibitor CMV UL56 terminase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Letermovir IV (Letermovir IV) — Merck Sharp & Dohme LLC. Letermovir inhibits the viral terminase enzyme of cytomegalovirus (CMV), preventing viral DNA packaging and replication.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Letermovir IV TARGET Letermovir IV Merck Sharp & Dohme LLC phase 3 CMV terminase inhibitor CMV UL56 terminase
Letermovir for secondary prophylaxis Letermovir for secondary prophylaxis Institute of Hematology & Blood Diseases Hospital, China marketed CMV terminase inhibitor CMV terminase (UL56 protein complex)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CMV terminase inhibitor class)

  1. Institute of Hematology & Blood Diseases Hospital, China · 1 drug in this class
  2. Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Letermovir IV — Competitive Intelligence Brief. https://druglandscape.com/ci/letermovir-iv. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: